NASDAQ NMS - GLOBAL MARKET · RLMD
-4.03% · -$0.2200 · Vol 3.2M
Market closed · last close 4:00 PM ET · price as of 16:00:01 ET
Relmada Therapeutics Inc

Relmada Therapeutics Inc

Pharmaceuticals
$5.24
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

Score not reportedVeridion does not publish a score-history trend for RLMD until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
NO SCORE SNAPSHOT COVERAGE
AI Analysis
Sovereign

Why is RLMD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for RLMD are being assembled.
About Relmada Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2014
Employees
17
Country
US

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$5.47
Day high
$5.70
Day low
$5.17
Previous close
$5.46
52W high
$7.86
-33.33% from high
52W low
$0.5631
64% of range
Market cap
$573.2M
EPS
$-1.4000
Beta
1.46
Shares out
105M
Volume
3.2M
1.43× rel vol
Avg volume
2.3M
VWAP
$5.43
Price history computed in-house
1W
-18.25%
1M
-22.14%
3M
-29.95%
1Y
+808.15%
YTD
+8.49%
SMA 50 $6.68 · below
SMA 200 $5.06 · above
52W position 64%
Veridion warehouse edge

Warehouse intelligence for RLMD.

Veridion Score
Not reported
Six-factor detail requires Sovereign.
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Related public evidence

Continue the RLMD research trail.

Relationship mapTrace receipt-backed holders and filings around RLMD.Congress disclosuresOpen receipt and filing context for RLMD.MethodologyReview score inputs, coverage rules, and limitations.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

Receipt-backed filing rows for RLMD are being assembled from the latest scheduled snapshot.

Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

RLMD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RLMD in this window.
Lobbying spend

RLMD lobbying filings, year to date.

Registered lobbying filings matched to Relmada Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RLMD in this window.
Latest news · RLMD
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for RLMD.
Options
Sovereign unlock shows live options positioning for RLMD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.